Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$1.56B-12.47%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Joseph T. Morrissey Jr.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 10,000
- Beta
- 1.52
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 1.25
Financials
Revenue
$1.56B-12.5%Net Income
$108.00M-84.6%EBITDA
$371.00M-59.4%Free Cash Flow
$65.00M-89.6%EPS (diluted)
$0.40-85.6%Shares Outstanding (diluted)
270.45M+6.8%Operating Expenses
$524.00MCash & Debt
$1.13BReturn of Capital
$6.00MDividend per Share
$0.02Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $6.22B | $187.00M | $0.72 |
| 2024 | $6.40B | $864.00M | $3.36 |
| 2023 | $6.26B | $1.02B | $4.01 |
| 2022 | $6.17B | $917.00M | $3.61 |
| 2021 | $6.30B | $1.35B | $5.33 |
| 2020 | $6.53B | $2.16B | $8.52 |
| 2019 | $7.78B | $3.22B | $12.71 |
| 2018 | $9.78B | $2.15B | $8.51 |
| 2017 | $10.50B | $1.80B | $7.11 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from OGN's reported EPS growth of -24.9% a year over 8 years. Historical EPS growth of -25% would project the company towards zero. Floored at -15% as a starting point.
- EPS in 5 years
- $0.32
- Implied price
- $3.20
- Return from $13.72
- -25.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $1.59 — -88.4% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 6 | 8 | 10 | 12 | 14 |
|---|---|---|---|---|---|
| -25.0% | -40.5% | -36.9% | -34.1% | -31.6% | -29.5% |
| -20.0% | -36.5% | -32.7% | -29.7% | -27.1% | -24.8% |
| -15.0% | -32.5% | -28.5% | -25.3% | -22.5% | -20.1% |
| -10.0% | -28.6% | -24.3% | -20.9% | -17.9% | -15.4% |
| -5.0% | -24.6% | -20.1% | -16.5% | -13.4% | -10.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (5)
- Newszacks.com·4d ago·Neutral
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
View source ↗ - Newszacks.com·15d ago·Positive
Is Trending Stock Organon & Co. (OGN) a Buy Now? Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
View source ↗ - Newsaccessnewswire.com·26d ago·Negative
Orogen Royalties Acquires the Serpent Gold Project in Nevada VANCOUVER, BC / ACCESS Newswire / September 10, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce the acquisition of the Serpent gold project in Nevada, USA. Project Highlights Serpent is a district scale, low-sulphidation epithermal gold target located in central Nevada Focused on a series of gold-bearing structures within an eight-kilometre trend of alteration Highly anomalous gol…
View source ↗ - Newszacks.com·28d ago·Neutral
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
View source ↗ - Newsbusinesswire.com·56d ago·Neutral
Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability JERSEY CITY, N.J.--(BUSINESS WIRE)--HCPs, healthcare settings and pharmacies can begin REMS certification for Organon's hormone-free copper IUD, MIUDELLA, ahead of upcoming launch.
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $0.88 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Jul 31$0.85 vs $0.85beat
- Thu, Apr 30$0.71 vs $0.83miss
- Thu, Feb 12$0.63 vs $0.73miss
- Mon, Nov 10$1.01 vs $0.93beat
- Tue, Aug 5$1.00 vs $0.94beat
- Thu, May 1$1.02 vs $0.89beat
Estimates and results for OGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by OGN officers and directors.
- Bought
- $353k
- Sold
- $553k
1 trade
2 trades
- Drinane Juliana Papasold
- Holzbaur Lynettesold
- Holzbaur Lynettebought
97 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Kevin Hernhouse · OK01 · disclosed Aug 13, 2026 (8d later)Sell$1,001 - $15,000
- Kevin Hernhouse · OK01 · disclosed Aug 11, 2026 (6d later)Sell$1,001 - $15,000
- Gary C. Peterssenate · MI · disclosed Nov 24, 2025 (137d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2023 (33d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (37d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Aug 7, 2023 (10d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 11, 2023 (12d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 12, 2023 (24d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed May 8, 2023 (13d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Apr 7, 2023 (24d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (30d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (29d later)Sell$50,001 - $100,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (34d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (30d later)Sell$50,001 - $100,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (28d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (34d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (28d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (22d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (22d later)Sell$100,001 - $250,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (21d later)Sell$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.